Clinical trials: AIDS and Infections
Hepatitis C
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
This is a randomized, multi-site, placebo-controlled trial of a fixed dose combination (FDC) of grazoprevir (MK-5172) 100 mg + elbasvir (MK-8742) 50 mg in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 1, GT4 or…
- Trial name
- NCT02252016
- Testing
- Grazoprevir + Elbasvir
- Volunteers
- 159 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study of 1592U89 in HIV-Infected Patients
The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).
- Trial name
- NCT00002388
- Testing
- Abacavir sulfate
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa
This is a double-blind, randomized, placebo-controlled Phase III study to assess the safety and efficacy of a silicone elastomer vaginal ring containing 25mg of dapivirine.
- Trial name
- NCT01337570
- Testing
- Dapivirine
- Where
- 5 sites in Malawi, Rwanda and 2 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Infection, Human Immunodeficiency Virus
Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects
Treatment of human immunodeficiency virus (HIV) infection requires daily oral administration of a combination of antiretroviral drugs to reduce the patient's HIV levels.
- Trial name
- NCT02373930
- Testing
- DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Mycobacterium Avium-intracellulare Infection, HIV Infections
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy.
- Trial name
- NCT00000971
- Testing
- Clarithromycin, Zidovudine, Didanosine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Abbott
H1N1 Influenza Virus, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01032408
- Testing
- Focetria®, Begrivac®
- Where
- 2 sites in Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Tuberculosis
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis…
- Trial name
- NCT02391415
- Testing
- VPM1002, BCG, VPM1002(Hyg+)
- Where
- 4 sites in South Africa
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW).
- Trial name
- PURPOSE 1 (NCT04994509)
- Testing
- Oral Lenacapavir (LEN), Subcutaneous (SC) Lenacapavir (LEN), F/TAF
- Where
- 28 sites in South Africa, Uganda
- Volunteers
- 5,368 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Candidiasis, Oral
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
The objectives of this study are to compare the efficacy and safety of Roxane's clotrimazole troches vs. Mycelex troches in HIV positive patients with oropharyngeal candidiasis, where this condition has been diagnosed by clinical…
- Trial name
- NCT02184351
- Testing
- Roxanes's clotrimazole troches, Mycelex® troches
- Volunteers
- 187 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Each year up to 22 million persons in the US are tested for HIV. Currently available "rapid" tests do not provide test results for at least 30 minutes from the collection of serum and plasma from the subject.
- Trial name
- NCT00514605
- Testing
- Behavioral counseling, HIV-1 Antibody Test Kit
- Where
- 14 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
HIV Infections, HIV Seronegativity
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.
- Trial name
- NCT00002231
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Hepatitis C Virus, HIV
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and…
- Trial name
- NCT02073656
- Testing
- LDV/SOF, RBV
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 335 people
- Sponsor
- Gilead Sciences
Infections, Human Immunodeficiency Virus and Hepatitis
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
This open-label, fixed-sequence crossover study aims to evaluate the effect of GSK1265744 (744) oral administration on the pharmacokinetics (PK) and pharmacodynamics (PD) of a commonly used oral contraceptive (OC) product…
- Trial name
- NCT02159131
- Testing
- Ethinyl Estadiol, Levonorgestrel, GSK1265744
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection
- Conditions
- HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer
- Trial name
- NCT03677960
- Testing
- Topical ABI-1968 cream
- Where
- 2 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Antiva Biosciences
HIV Infections
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2)…
- Trial name
- NCT00005017
- Testing
- Ritonavir, Abacavir sulfate, Amprenavir
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Glaxo Wellcome
Health Risk Behaviors
Sexually Active Adolescent Focused Education
SAAFE will be pilot tested in 2 geographically distinct areas (Washington, DC and Deep South) with 100 participants from each site to 1) primarily assess the efficacy of improved self-efficacy, knowledge about HIV/STIs and…
- Trial name
- SAAFE (NCT03646032)
- Testing
- SAAFE, Control
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Benten Technologies, Inc.
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Diffuse Large B Cell Lymphoma, Kaposi Sarcoma
Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640…
- Trial name
- ABC-102 (NCT02229981)
- Testing
- ABC294640
- Where
- United States
- Sponsor
- RedHill Biopharma Limited
HIV Infections
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with…
- Trial name
- NCT00517192
- Testing
- Tipranavir, Darunavir, Ritonavir
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.